Literature DB >> 19506815

The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood.

Michael C Kruer1,2, Allen M Kaplan3, Michael M Etzl4, David F Carpentieri5, Paul S Dickman5, Kewei Chen6, Kathleen Mathieson7, Alison Irving6.   

Abstract

Astrocytomas are the most common brain tumors of childhood and adolescence. Low-grade astrocytomas (LGAs), in general, have favorable prognosis, but recurrence or progressive disease with dissemination, malignant transformation, and death occur in some cases. Current clinical and pathological measures including age, sex, imaging characteristics, location and size of the tumor, histopathology, and degree of resection cannot predict with certainty which tumors will demonstrate aggressive behavior. The objective of the study is to determine the predictive value of positron emission tomography (PET) and a proliferation index (PI) in identifying high risk LGAs. We reviewed 46 cases ages 5 months to 17 years with low-grade (WHO I-II) astrocytomas. All patients had PET scans utilizing [(18)F] fluorodeoxyglucose (FDG) and 24 cases had measurements with Ki-67/MIB-1 immunohistochemistry. Review of our data confirmed progressive disease (PD) in 18/46 (39%) of cases with 9/21 (42%) occurring after subtotal resection and 9/25 (36%) after gross total resection. The mortality rate was 5/46 (10.8%). Tumors with FDG hypermetabolism were significantly more likely to demonstrate aggressive behavior and PD. Increased PI values also suggested PD. Progression-free survival and time to progression were significantly longer for patients with hypometabolic scans. Time to progression was significantly longer with lower PI values. Results demonstrate that PET and PI are useful measures in the identification and stratification of high risk LGAs. The ability to identify a subset of progressive LGAs earlier may suggest the need for second-look neurosurgical procedures or more intensified adjuvant treatment that may ultimately improve outcome and survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506815     DOI: 10.1007/s11060-009-9922-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  [Contribution of PET to the management of patients with low-grade glioma].

Authors:  O De Witte; N Oulad Ben Taib; F Branle; S Rorive; J Brotchi; S Goldman
Journal:  Neurochirurgie       Date:  2004-09       Impact factor: 1.553

2.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

3.  The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms.

Authors:  Richard A Prayson
Journal:  Adv Anat Pathol       Date:  2005-05       Impact factor: 3.875

4.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

Authors:  June-Key Chung; Yu Kyeong Kim; Seok-ki Kim; Yong Jin Lee; Suntta Paek; Jeong Seok Yeo; Jae Min Jeong; Dong Soo Lee; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

5.  Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.

Authors:  Kenji Torii; Naohiro Tsuyuguchi; Joji Kawabe; Ichiro Sunada; Mitsuhiro Hara; Susumu Shiomi
Journal:  Ann Nucl Med       Date:  2005-12       Impact factor: 2.668

6.  Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children.

Authors:  Benoit Pirotte; Serge Goldman; Patrick Van Bogaert; Philippe David; David Wikler; Sandrine Rorive; Jacques Brotchi; Marc Levivier
Journal:  Neurosurgery       Date:  2005-07       Impact factor: 4.654

7.  Positron emission tomography using [18F] fluorodeoxyglucose and [11C] l-methionine to metabolically characterize dysembryoplastic neuroepithelial tumors.

Authors:  A M Kaplan; M A Lawson; J Spataro; D J Bandy; C T Bonstelle; S D Moss; K H Manwaring; E M Reiman
Journal:  J Child Neurol       Date:  1999-10       Impact factor: 1.987

8.  MIB-1 proliferation index predicts survival among patients with grade II astrocytoma.

Authors:  P E McKeever; M S Strawderman; B Yamini; A A Mikhail; M Blaivas
Journal:  J Neuropathol Exp Neurol       Date:  1998-10       Impact factor: 3.685

Review 9.  Prospective clinical trials of intracranial low-grade glioma in adults and children.

Authors:  Edward G Shaw; Jeffrey H Wisoff
Journal:  Neuro Oncol       Date:  2003-07       Impact factor: 12.300

10.  Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography.

Authors:  Meri Utriainen; Liisa Metsähonkala; Toivo T Salmi; Tapio Utriainen; Hannu Kalimo; Helena Pihko; Anne Mäkipernaa; Arja Harila-Saari; Sirkku Jyrkkiö; Jukka Laine; Kjell Någren; Heikki Minn
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

View more
  18 in total

Review 1.  PET/CT in paediatric oncology: clinical usefulness and dosimetric concerns.

Authors:  Giovanni Lucignani; Diego De Palma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01       Impact factor: 9.236

2.  Use of positron emission tomography scanning to evaluate pseudoresponse.

Authors:  Peter D Kim; Walter A Hall
Journal:  Transl Pediatr       Date:  2013-04

Review 3.  Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours.

Authors:  Giovanni Lucignani; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05       Impact factor: 9.236

4.  Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.

Authors:  Katherine A Zukotynski; Frederic H Fahey; Sridhar Vajapeyam; Sarah S Ng; Mehmet Kocak; Sridharan Gururangan; Larry E Kun; Tina Y Poussaint
Journal:  J Nucl Med       Date:  2013-06-25       Impact factor: 10.057

Review 5.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

6.  (18)F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors.

Authors:  Martin Misch; Andreas Guggemos; Pablo Hernáiz Driever; Arend Koch; Frederik Grosse; Ingo G Steffen; Michail Plotkin; Ulrich-Wilhelm Thomale
Journal:  Childs Nerv Syst       Date:  2014-09-18       Impact factor: 1.475

7.  Incidental brain tumors in children: an international neurosurgical, oncological survey.

Authors:  Jonathan Roth; Jehuda Soleman; Dimitris Paraskevopoulos; Robert F Keating; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2018-05-25       Impact factor: 1.475

8.  Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Jason Fangusaro; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Frederic Fahey; Sridhar Vajapeyam; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Maryam Fouladi; Larry E Kun
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 9.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

Review 10.  PET and SPECT studies in children with hemispheric low-grade gliomas.

Authors:  Csaba Juhász; Edit Bosnyák
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.